The application of adalimumab in the treatment of children with inflammatory bowel disease
- VernacularTitle:阿达木单克隆抗体在儿童炎症性肠病治疗中的应用初探
- Author:
Fengfan WANG
1
;
Yanan HAN
1
;
Xiaoxia REN
1
;
Lina SUN
1
;
Jiameng YAO
1
;
Ying FANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Adalimumab; Inflammatory bowel disease; Children; Infliximab
- From: Chinese Journal of Inflammatory Bowel Diseases 2021;05(3):267-270
- CountryChina
- Language:Chinese
- Abstract: The occurrence of inflammatory bowel disease (IBD) may be related to a variety of cytokines, and the blocking of tumor necrosis factor (TNF) -α signaling pathway has been an important therapeutic target of IBD. Adalimumab is a fully humanized anti-TNF-α monoclonal antibody with low immunogenicity. It may be considered for better efficacy in children with IBD who failed infliximab therapy.
